<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6359">
  <stage>Registered</stage>
  <submitdate>18/09/2016</submitdate>
  <approvaldate>18/09/2016</approvaldate>
  <nctid>NCT02913261</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation</studytitle>
    <scientifictitle>A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation</scientifictitle>
    <utrn />
    <trialacronym>REACH2</trialacronym>
    <secondaryid>CINC424C2301</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Corticosteroid Refractory Acute Graft vs Host Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ruxolitinib
Treatment: drugs - Best Available Therapy (BAT)

Active Comparator: Ruxolitinib - Ruxolitinib 10 mg Bis In Diem (BID)

Active Comparator: Best Available Therapy (BAT) - As selected by the investigator


Treatment: drugs: Ruxolitinib
Tablet for oral use

Treatment: drugs: Best Available Therapy (BAT)
Best Available Therapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall Response Rate (ORR) - ORR is defined as the proportion of patients with a best overall response defined as complete response or partial response</outcome>
      <timepoint>28 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Durable Overall Response Rate - Proportion of all patients in each arm who achieve a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintain a CR or PR at Day 56.</outcome>
      <timepoint>Day 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ORR - Proportion of patients who achieved ORR (CR+PR) at Day 14</outcome>
      <timepoint>Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) - DOR is the time from first response until acute Graft versus Host Disease (aGvHD) progression or the date of additional systemic therapies for aGvHD.</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative steroid dose - Weekly cumulative steroid dose for each subject up to Day 56 or end of treatment</outcome>
      <timepoint>56 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - OS is defined as the time from the date of randomization to the date of death due to any cause.</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event-free survival - Event-free survival, defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause.</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Failure-Free survival (FFS) - FFS is defined as the time from the date of randomization to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment.</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non Relapse Mortality (NRM) - NRM is defined as the time from date of randomization to date of death not preceded by hematologic disease relapse/progression</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Malignancy Relapse/Progression (MR) - MR is defined as the time from date of randomization to hematologic malignancy relapse/progression. Calculated for patients with underlying hematologic malignant disease.</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of chronic Graft versus Host Disease (cGvHD) - cGvHD, defined as the diagnosis of any cGvHD including mild, moderate, severe</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) parameter: Plasma concentration at peak (CMax) after single dose and at steady state of ruxolitinib in corticosteroid refractory acute GvHD patients - plasma concentration at peak (Cmax)Ruxolitinib after a single dose and at steady state</outcome>
      <timepoint>168 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exposure-efficacy relationship of ruxolitinib in corticosteroid refractory aGvHD - exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect (effect: overall response rate at Day 28 and durable response at Day 56; Overall survival at 6 months)</outcome>
      <timepoint>168 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Reported Outcomes (PROs): Change in Functional Assesment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) from baseline</outcome>
      <timepoint>Baseline, Up to 30 day follow-up visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Reported Outcomes (PROs): Change in EuroQol-5D (EQ-5D) from baseline</outcome>
      <timepoint>Baseline, Up to 30 day follow-up visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) parameter: Area Under the Curve (AUC) after single dose and at steady state of ruxolitinib in corticosteroid refractory acute GvHD patients - AUC from time zero to the last measurable concentration sampling time and from time zero to infinity, and Accumulation ratio (Racc). Ruxolitinib after a single dose and at steady state. AUC at end of a dosing interval (AUC tau) at steady state.</outcome>
      <timepoint>168 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) parameter: total body clearance of ruxolitinib from the plasma after single dose and at steady state of ruxolitinib in corticosteroid refractory acute GvHD patients - total body clearance of ruxolitinib from the plasma after a single dose and at steady state</outcome>
      <timepoint>168 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) parameter: apparent volume of distribution during terminal phase after single dose and at steady state of ruxolitinib in corticosteroid refractory acute GvHD patients - apparent volume of distribution during terminal phase after a single dose and at steady state</outcome>
      <timepoint>168 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have undergone Allogeneic Stem Cell Transplanttaion (alloSCT) from any donor source
             (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral
             blood stem cells, or cord blood. Recipients of non- myeloablative, myeloablative, and
             reduced intensity conditioning are eligible

          -  Clinically diagnosed Grades II to IV acute GvHD as per standard criteria occurring
             after alloSCT requiring systemic immune suppressive therapy. Biopsy of involved organs
             with aGvHD is encouraged but not required for study screening.

          -  Confirmed diagnosis of steroid refractory aGvHD defined as patients administered
             high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent
             prednisone dose 2.5 mg/kg/day]), given alone or combined with calcineurin inhibitors
             (CNI) and either:

               -  Progressing based on organ assessment after at least 3 days compared to organ
                  stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for
                  the treatment of Grade II-IV aGvHD, OR

               -  Failure to achieve at a minimum partial response based on organ assessment after
                  7 days compared to organ stage at the time of initiation of high-dose systemic
                  corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD,OR

               -  Patients who fail corticosteroid taper defined as fulfilling either one of the
                  following criteria:

          -  Requirement for an increase in the corticosteroid dose to methylprednisolone =2
             mg/kg/day (or equivalent prednisone dose =2.5 mg/kg/day) , OR

          -  Failure to taper the methylprednisolone dose to &lt;0.5 mg/kg/day (or equivalent
             prednisone dose &lt;0.6 mg/kg/day) for a minimum 7 days.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Has received more than one systemic treatment for steroid refractory aGvHD.

          -  Presence of an active uncontrolled infection including significant bacterial, fungal,
             viral or parasitic infection requiring treatment. Infections are considered controlled
             if appropriate therapy has been instituted and, at the time of screening, no signs of
             progression are present. Progression of infection is defined as hemodynamic
             instability attributable to sepsis, new symptoms, worsening physical signs or
             radiographic findings attributable to infection. Persisting fever without other signs
             or symptoms will not be interpreted as progressing infection.

          -  Evidence of uncontrolled viral infection including Cytomegalovirus (CMV), Epstein-Barr
             Virus (EBV), Human Herpes Virus-6 (HHV-6), Hepatitis Virus (HBV), or Hepatitis C Virus
             (HCV) based on assessment by the treating physician.

          -  Presence of relapsed primary malignancy, or who have been treated for relapse after
             the alloHSCT was performed, or who may require rapid immune suppression withdrawal as
             pre-emergent treatment of early malignancy relapse.

        Other protocol-defined inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>10/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>308</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>9/04/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Westmead</hospital>
    <hospital>Novartis Investigative Site - Herston</hospital>
    <hospital>Novartis Investigative Site - Parkville</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3002 - Parkville</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besancon cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 08</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre-Benite Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tübingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wiesbaden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>AN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>FI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>GE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>UD</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyagi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Göteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety and efficacy of ruxolitinib compared to Best Available Therapy in
      patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem
      cell transplantation</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02913261</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone>+41613241111</phone>
      <fax />
      <email>trialandresults.registries@novartis.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>